India targets $1 trillion bioeconomy by 2047, $300 billion by 2030
Synopsis
Key Takeaways
India has set an ambitious roadmap to grow its bioeconomy to $300 billion by 2030 and further to $1 trillion by 2047, Union Minister Dr. Jitendra Singh announced on Saturday, 21 November 2026, emphasising the need for sharper scientific innovation, faster commercialisation of research, and deeper industry participation to reach those milestones.
The minister was speaking at the 4th Annual General Meeting (AGM) of the Biotechnology Research and Innovation Council (BRIC) Society in New Delhi, where he outlined the scale of progress already achieved — and the distance still to travel.
From $10 Billion to $195 Billion: The Growth So Far
Singh underscored that India's bioeconomy has expanded from roughly $10 billion to more than $195 billion in recent years, a trajectory he described as evidence of science, technology, and innovation becoming increasingly central to the country's economic growth. The jump represents a near-twenty-fold increase and places India among the fastest-growing bioeconomies globally.
He called out the need to push this growth further, stressing that scientific achievements must move beyond publications and patents to deliver tangible technologies, products, and solutions for citizens.
What BRIC Represents and Why It Matters
Singh described BRIC's model — integrating multiple biotechnology research institutions under a shared-resources and collaborative-governance framework — as one of the first of its kind in India. He noted it has since inspired similar approaches in other organisations, calling it 'a new approach to scientific institution-building where institutions work collectively, share capabilities and pursue multidisciplinary research while retaining their individual strengths.'
At the AGM, Department of Biotechnology Secretary and BRIC Director General Rajesh S. Gokhale presented an overview of the council's activities and achievements, covering governance reforms, research collaborations, and future priorities.
Notably, BRIC ranked first among government institutions in health sciences and second in biological sciences in India for the second consecutive year, according to the Nature Index India — a credible international benchmark for research output and quality.
Research Focus Areas and Key Sectors
The minister highlighted ongoing BRIC research across healthcare, agriculture, animal health, advanced materials, and biotechnology platforms. Specific areas of work cited include diagnostics, therapeutics, disease detection, climate-resilient agriculture, and sustainable biomaterials — sectors with direct civilian and economic impact.
Singh called for stronger academia-industry linkages, arguing that scientists, entrepreneurs, investors, and businesses must collaborate from the earliest stages of technology development to accelerate the path from laboratory to market.
Startups, Students, and the Innovation Pipeline
The minister pointed to India's biotechnology startup ecosystem, which now comprises more than 11,000 startups, as a sign of growing commercial momentum. He urged young scientists to focus on product development, technology translation, and enterprise creation rather than research output alone.
He also highlighted the government's D.E.S.I.G.N. for BioE3 Challenge, which has received more than 6,000 proposals from school students and citizens — a signal, he argued, of broad public interest in biotechnology innovation at the grassroots level.
With the 2047 centenary target now formally articulated alongside a nearer-term 2030 benchmark, the government appears to be framing biotechnology as a core pillar of its long-range economic strategy — one where execution and commercialisation will matter as much as research ambition.